Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-02
2005-08-02
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S006900, C435S001100, C435S001200, C530S380000, C530S392000, C530S395000, C530S416000, C530S417000, C530S422000, C530S830000, C530S831000
Reexamination Certificate
active
06924267
ABSTRACT:
The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or a mixture thereof. Alternatively, organ or tissue transplants can be contacted with natural alpha-1 acid glycoprotein, natural alpha-antitrypsin or mixtures by perfusing or flushing them with a solution containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures thereof in a concentration of 0.1 to 5 g/l.
REFERENCES:
patent: 2003/0069174 (2003-04-01), Pichler et al.
patent: WO 97/32893 (1997-09-01), None
Daemen et al., Circulation, vol. 102, No. 12, pp. 142-1426, Sep. 19, 2000.
Collard, Charles D et al., “Pathophysiology, clinical manifestations . . . ”, Anesthesiology, vol. 94, No. 6, Jun. 2001, pp. 1133-1138.
Squifflet, J. P. et al., “Safe preservation of human renal . . . ”, Transplantation Proceedings, vol. XIII, No. 1, Mar. 1981, pp. 693-696.
Maxwell, Simon R.J. et al., “Reperfusion injury: a review . . . ”, International Journal of Cardiology, (1997) vol. 59, pp. 95-117.
Daemen, Marc A. R. C. et. al., “Inhibition of apoptosis induced by . . . ”, The Journal of Clinical Investigation, Spetember 1999, vol. 104, No. 5, pp. 541-549.
Molle, Wim Van et al., “α1-Acid glycoprotein and α1-Antitrypsin inhibit . . . ”, The Journal Immunology, (Oct 1, 1997), 159(7), pp. 3555-3564.
Williams, Julian P. et al., “α1-Acid glycoprotein reduces local . . . ”, American Journal of Physiology, Nov 1997, 273 (5 Pt 1), p. G1031-5.
Huang, Jianmin et al., “Expression and purification of functional . . . ”, Biotechnol. Prog., (2001), 17, pp. 126-133.
Burnouf-Radosevich, M. et al., “Nanofiltration, a new specific virus . . . ”, Vox Sang, (1994) 67, pp. 132-138.
Hao, Yu-Lee et al., “Development of large-scale fractionaiton methods IV . . . ”Biochim Biophys Acta., Sep 21 1973, 322(1), pp. 99-108.
Daemen, Marc A.R.C. et al., “Functional protein by acute . . . ”, Circulation, Sep 19 2000, 102(12), p. 1420-6.
De Graaf, Truus W., “Inflammation-induced expression of sialyl . . . ”, J Exp Med., Mar 1, 1993, 177(3), pp. 657-66.
Pichler, et al., Preclinical investigatios of α1-acid glycoportein (orosomucoid), Wien Klin Wochenschr (the middle european journal of medicine) (1999) 111/5: 192-198.
Buurman Wim A.
Daemen Marc A. R. C.
Denecker Geertrui
Heemskerk Vincent H.
Parkkinen Jaakko
Birch & Stewart Kolasch & Birch, LLP
Mohamed Abdel A.
Suomen Punainen Risti Veripalvelu
Weber Jon
LandOfFree
Methods and active substances for protecting organs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and active substances for protecting organs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and active substances for protecting organs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470091